Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Unit, U.S. Pharma See Mixed Results From IBD Drug Trials

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical's U.S. unit and Sucampo Pharmaceuticals report mixed results from a pair of Phase III studies on Sucampo's Amitiza (lubiprostone) to treat opioid-induced bowel dysfunction. One trial met goals; the other fell short. Amitiza has U.S. clearance to treat chronic idiopathic constipation, but the trials for the other indication indicated the companies need to continue a separate study not expected to yield data until later this year. If that study is successful, the drug makers expect to apply to the U.S. FDA for approval next year. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel